![Postoperative Pain Market to Rising Steadily at a 7.93% CAGR Owing to Growing Number of Surgeries, During the Study Period [2018-2030], Says DelveInsight](https://newzznow.com/wp-content/uploads/2021/06/DelveInsight_Logo.jpg){kind=logo}
LAS VEGAS, June 30, 2021 /PRNewswire/ — DelveInsight’s “Postoperative Pain Market” report provides a thorough comprehension of the Postoperative Pain historical and forecasted epidemiology and the Postoperative Pain market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Postoperative Pain market report also proffers an analysis of the current Postoperative Pain treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the necessary takeaways from the Postoperative Pain Market Research Report
- Opioids, NSAIDs, and anesthetics mainly cover the current Postoperative Pain market. Current treatment for Postoperative Pain involves approved drugs such as Anjeso, Dextenza, Inveltys, and others in nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
- Some approved opioids medications are also present in the Postoperative Pain market, such as Dsuvia, approved in 2018 in both US and EU. Some other approved drugs that are being used in Postoperative Pain are Penthrox and Exparel.
- Korsuva (CR845), Co-crystal E-58425 (Tramadol/Celecoxib), Zalviso (sufentanil), Tramadol IV, Zynrelef (bupivacaine and meloxicam), Posimir (Bupivacaine Solution), Olinvyk (oliceridine), Xaracoll (bupivacaine hydrochloride), and others are the pipeline candidates, which are expected to enter the Postoperative Pain Market in the forecast period (2021–2030).
- The growth of the…
